In the last trading session, 5.81 million Sangamo Therapeutics Inc (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.19. With the company’s per share price at $0.47 changed hands at $0.02 or 4.44% during last session, the market valuation stood at $115.34M. SGMO’s last price was a discount, traded about -576.6% off its 52-week high of $3.18. The share price had its 52-week low at $0.30, which suggests the last value was 36.17% up since then.
Analysts gave the Sangamo Therapeutics Inc (SGMO) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.71. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended SGMO as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Sangamo Therapeutics Inc’s EPS for the current quarter is expected to be -0.1.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Instantly SGMO was in green as seen at the end of in last trading. With action -32.88%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -53.92%, with the 5-day performance at -32.88% in the red. However, in the 30-day time frame, Sangamo Therapeutics Inc (NASDAQ:SGMO) is -31.42% down.
The consensus price target for the stock as assigned by Wall Street analysts is 2.5, meaning bulls need an upside of 81.2% from its current market value. According to analyst projections, SGMO’s forecast low is 2 with 3 as the target high. To hit the forecast high, the stock’s price needs a -538.3% plunge from its current level, while the stock would need to soar -325.53% for it to hit the projected low.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Year-over-year growth is forecast to reach -15.67% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 29.9M. 6 analysts are of the opinion that Sangamo Therapeutics Inc’s revenue for the current quarter will be 5.83M. The company’s revenue for the corresponding quarters a year ago was 356k and 49.41M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 8,298.88%. The estimates for the next quarter sales put growth at -88.19%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.57%. The 2025 estimates are for Sangamo Therapeutics Inc earnings to increase by 25.07%, but the outlook for the next 5-year period is at 20.66% per year.
SGMO Dividends
Sangamo Therapeutics Inc is expected to release its next quarterly earnings report in June.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 6.894% or 14.06 million shares worth $5.04 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund . With 5.65 shares estimated at $2.65 million under it, the former controlled 2.42% of total outstanding shares. On the other hand, WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund held about 1.94% of the shares, roughly 4.53 shares worth around $2.13 million.
